BIO Asia–Taiwan 2021 亞洲生技大會

BIO Asia–Taiwan 2021 亞洲生技大會

講師

St Vincent’s Hospital Melbourne

Company Info

Name /St Vincent’s Hospital Melbourne

Address /41 Victoria Parade, Fitzroy VIC 3065

Website /www.svhm.org.au/research

Presenter

Name /Tam Nguyen

Title /Associate Professor

Email /tam.nguyen@svha.org.au

Telephone /(Work) +61 9231 3930

Fax /

Mobile /

Company Type

Others:Hospital/Service Provider

About the Company

St Vincent’s Hospital Melbourne is part of the St Vincent’s Health Australia, a $2 billion not-for-profit health and aged care provider. We’re the second largest healthcare provider with more than 30 facilities along the eastern seaboard. SVHM is one of five tertiary teaching hospitals in Victoria. Our clinical care is supported by an inspiring and very active translational research program:

  • Oncology / haematology – breast and lung cancer
  • Gastroenterology – NASH, hepatitis B/C, IBD
  • Neurosciences – epilepsy, Parkinson’s disease, neurosurgery
  • Cardiology – interventional, devices, clinical management
  • Endocrinology – diabetes, devices, complications
  • Renal medicine
  • Regenerative medicine
  • Immunology/inflammation/infection/sepsis
  • Orthopaedics – sarcoma, limb reconstruction
  • Respiratory – ɑ1 anti-trypsin deficiency
  • Bioengineering: stem cells, 3-D Printing

Our Research Valet® 研究协助服务is a unique facilitated fast IRB submission program that can work with sponsors and researchers to fast-track clinical trial start-up.

Brief Description of main products or services

Research Valet® 研究协助服务

St Vincent’s innovative Research Valet® service provides sponsors a smooth start up with highly competitive timeline to gain ethics (IRB) approval. Post approval management services facilitates all ongoing ethics and governance management as a complete Lead Site Solution.

  • NO IND required in Australia
  • Single point of access for all regulatory advice for Australia
  • Speed start-up time for Australian clinical trials (Phase I-IV)
  • Ethics outcomes within 30 days of committee meeting (Phase II-IV)
  • Start-up to full study management options
  • Ethics approval from single HREC for all Australian states (except NT)
    • 在此可获取澳大利亚所有监管意见
    • 缩短澳大利亚临床试验(I期—IV期)的启动时间
    • 30日内获得伦理审查结果
    • 启动至全面研究的管理方案选择
    • 获得的HREC伦理审批在澳大利亚各州均可使用(不含北领地)
    • 圣文森特医院无需成为试验场地

w: Www.researchvalet.com.au e: valet@svha.org.au w: http://www.researchvalet.com.au/ch/

Contact:

Dr Megan Robertson, Director of Research
e: megan.robertson@svha.org.au

Dr Tam Nguyen, Deputy Director of Research
e: tam.nguyen@svha.org.au

Contact Person

Name /

Email /

Phone /